Ars Pharmaceuticals [SPRY] vs Vertex [VRTX] Detailed Stock Comparison
Ars Pharmaceuticals
NASDAQ
Loading...
Vertex
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Ars Pharmaceuticals wins in 3 metrics, Vertex wins in 15 metrics, with 0 ties. Vertex appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Ars Pharmaceuticals | Vertex | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 168.25 | 28.08 | Vertex |
| Price-to-Book Ratio | 6.93 | 5.90 | Vertex |
| Debt-to-Equity Ratio | 38.28 | 8.89 | Vertex |
| PEG Ratio | 0.66 | -0.22 | Vertex |
| EV/EBITDA | -19.88 | 20.09 | Ars Pharmaceuticals |
| Profit Margin (TTM) | -42.74% | 31.86% | Vertex |
| Operating Margin (TTM) | -302.95% | 38.93% | Vertex |
| EBITDA Margin (TTM) | N/A | 38.93% | N/A |
| Return on Equity | -23.56% | 22.77% | Vertex |
| Return on Assets (TTM) | -13.85% | 13.09% | Vertex |
| Free Cash Flow (TTM) | $12.99M | $-978.00M | Ars Pharmaceuticals |
| 1-Year Return | 4.17% | -17.90% | Ars Pharmaceuticals |
| Price-to-Sales Ratio (TTM) | 11.88 | 8.87 | Vertex |
| Enterprise Value | $1.17B | $96.45B | Vertex |
| EV/Revenue Ratio | 10.39 | 8.45 | Vertex |
| Gross Profit Margin (TTM) | 68.29% | 86.25% | Vertex |
| Revenue per Share (TTM) | $1 | $44 | Vertex |
| Earnings per Share (Diluted) | $-0.48 | $14.07 | Vertex |
| Beta (Stock Volatility) | 0.96 | 0.44 | Vertex |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Ars Pharmaceuticals vs Vertex Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Ars Pharmaceuticals | -9.21% | -7.09% | -23.25% | -7.02% | 24.65% | 26.05% |
| Vertex | -0.59% | 0.59% | -15.96% | -8.96% | -17.97% | -2.62% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Ars Pharmaceuticals | 4.17% | 157.63% | -46.00% | 227.67% | 227.67% | 227.67% |
| Vertex | -17.90% | 40.27% | 46.36% | 194.76% | 1,046.94% | 2,164.30% |
Performance & Financial Health Analysis: Ars Pharmaceuticals vs Vertex
| Metric | SPRY | VRTX |
|---|---|---|
| Market Information | ||
| Market Cap | $1.33B | $101.31B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 2,565,590 | 1,787,010 |
| 90 Day Avg. Volume | 1,634,343 | 2,014,950 |
| Last Close | $13.50 | $395.12 |
| 52 Week Range | $10.00 - $18.90 | $362.50 - $519.88 |
| % from 52W High | -28.57% | -24.00% |
| All-Time High | $63.41 (Mar 15, 2021) | $519.88 (Nov 04, 2024) |
| % from All-Time High | -78.71% | -24.00% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 30.43% | 0.12% |
| Quarterly Earnings Growth | 30.43% | 0.12% |
| Financial Health | ||
| Profit Margin (TTM) | -0.43% | 0.32% |
| Operating Margin (TTM) | -3.03% | 0.39% |
| Return on Equity (TTM) | -0.24% | 0.23% |
| Debt to Equity (MRQ) | 38.28 | 8.89 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $1.95 | $67.02 |
| Cash per Share (MRQ) | $2.43 | $24.90 |
| Operating Cash Flow (TTM) | $-52,797,000 | $3.85B |
| Levered Free Cash Flow (TTM) | $-26,907,750 | $2.91B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Ars Pharmaceuticals vs Vertex
| Metric | SPRY | VRTX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 168.25 | 28.08 |
| Forward P/E | -17.76 | 21.05 |
| PEG Ratio | 0.66 | -0.22 |
| Price to Sales (TTM) | 11.88 | 8.87 |
| Price to Book (MRQ) | 6.93 | 5.90 |
| Market Capitalization | ||
| Market Capitalization | $1.33B | $101.31B |
| Enterprise Value | $1.17B | $96.45B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 10.39 | 8.45 |
| Enterprise to EBITDA | -19.88 | 20.09 |
| Risk & Other Metrics | ||
| Beta | 0.96 | 0.44 |
| Book Value per Share (MRQ) | $1.95 | $67.02 |
Financial Statements Comparison: Ars Pharmaceuticals vs Vertex
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SPRY | VRTX |
|---|---|---|
| Revenue/Sales | $15.72M | $2.96B |
| Cost of Goods Sold | $4.98M | $407.50M |
| Gross Profit | $10.73M | $2.56B |
| Research & Development | $4.04M | $978.40M |
| Operating Income (EBIT) | $-47.61M | $1.15B |
| EBITDA | $-47.61M | $1.34B |
| Pre-Tax Income | $-44.88M | $1.28B |
| Income Tax | N/A | $250.10M |
| Net Income (Profit) | $-44.88M | $1.03B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SPRY | VRTX |
|---|---|---|
| Cash & Equivalents | $39.86M | $4.67B |
| Total Current Assets | $303.86M | $10.01B |
| Total Current Liabilities | $27.62M | $3.78B |
| Long-Term Debt | N/A | $1.65B |
| Total Shareholders Equity | $228.97M | $16.50B |
| Retained Earnings | $-157.25M | $10.25B |
| Property, Plant & Equipment | $1.15M | $2.63B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SPRY | VRTX |
|---|---|---|
| Operating Cash Flow | $-40.11M | $404.90M |
| Capital Expenditures | $-91,000 | $-40.70M |
| Free Cash Flow | $-40.83M | $778.20M |
| Debt Repayment | N/A | $-1.30M |
| Common Stock Repurchase | N/A | $-696.60M |
Short Interest & Institutional Ownership Analysis
| Metric | SPRY | VRTX |
|---|---|---|
| Shares Short | 15.34M | 4.36M |
| Short Ratio | 11.21 | 4.04 |
| Short % of Float | 0.26% | 0.02% |
| Average Daily Volume (10 Day) | 2,565,590 | 1,787,010 |
| Average Daily Volume (90 Day) | 1,634,343 | 2,014,950 |
| Shares Outstanding | 97.95M | 256.94M |
| Float Shares | 55.27M | 255.58M |
| % Held by Insiders | 0.17% | 0.00% |
| % Held by Institutions | 0.86% | 0.98% |
Dividend Analysis & Yield Comparison: Ars Pharmaceuticals vs Vertex
| Metric | SPRY | VRTX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |